创始人以第一作者发表的代表性研究，与分类器的真实输出——可作为科研合作能力的直接佐证。Selected first-author studies and real classifier output — direct evidence of our research-collaboration capability.
我们对外提供完整的中枢神经系统肿瘤甲基化临床研究科研服务：从样本检测、本地队列模型验证，到聚类与数据分析，再到课题与文章的设计思路和方法学指导。End-to-end research services for CNS-tumor methylation studies — assay and local-cohort model validation, clustering and data analysis, and study & manuscript design.
芯片 / 纳米孔甲基化检测，经 AICNS 分类器判读，并在你的本地样本队列上完成模型验证与阈值校准。Array / Nanopore methylation profiling, read by the AICNS classifier, with model validation and threshold calibration on your local cohort.
t-SNE / UMAP 聚类与降维可视化，以及从原始数据到结果的完整生物信息学处理。t-SNE/UMAP clustering and dimensionality reduction, plus a complete bioinformatics pipeline from raw data to results.
从选题、研究设计到投稿，提供贴近临床真实验证情况的科研方向与方法学指导。From topic and study design to submission — research direction and methodology grounded in real-world clinical validation.
我们的分类引擎不仅追求准确率，更强调可校准的置信度与对不确定性的诚实表达——这正是高质量甲基化分类算法的核心。Our engine optimizes not only accuracy but calibrated confidence and an honest treatment of uncertainty — the core of a high-quality methylation-classification algorithm.
先剔除平台间系统性差异最大的 CpG，再以最近质心（平台稳健的相关系数）与随机森林双读集成，并经温度校准给出可比概率。EPICv2 严格作为独立验证集，不参与训练或调参。After removing the CpGs most affected by cross-platform bias, a nearest-centroid and random-forest dual read are ensembled and temperature-calibrated. EPICv2 is held out strictly for independent validation.
在分类之外提供拷贝数变异、MGMT-STP27 启动子甲基化状态、UMAP/t-SNE 临近群定位，以及肿瘤纯度与微环境解卷积，构成完整、可解释的证据链。Beyond classification: copy-number variation, MGMT-STP27 status, UMAP/t-SNE localization, and deconvolution of tumor purity and microenvironment — a complete, interpretable evidence chain.
默赛生基因科技专注于基于 DNA 甲基化谱的肿瘤分类研究。我们整合全球公开甲基化数据集与本地临床样本，构建肿瘤甲基化表型分类模型，致力于攻克中枢神经系统（CNS）肿瘤、尤其是儿童脑肿瘤的分类难题。Mosaisheng Gene Technology focuses on DNA-methylation-based tumor classification research. By integrating globally available reference datasets with locally curated clinical samples, we build methylation-phenotype classification models to tackle the classification challenges of central nervous system (CNS) tumors — pediatric brain tumors in particular.
通过整合尖端甲基化检测、前沿计算方法与深厚的神经病理专业知识，我们提供精确、可靠、可解释的肿瘤分类科研解决方案与算法模型。Combining advanced methylation assays, state-of-the-art computation and deep neuropathology expertise, we deliver accurate, reliable and interpretable classification research solutions and algorithmic models.
依托与临床及科研伙伴的广泛合作，我们致力于把前沿方法学转化为可操作的科研课题合作与分类模型方案，推动神经肿瘤学研究的创新。Through extensive collaboration with clinical and research partners, we translate frontier methodology into actionable research collaborations and classification-model solutions that advance neuro-oncology research.
方法学承袭 Heidelberg / DKFZ 神经病理甲基化分类体系，对标国际标准。Methodology rooted in the Heidelberg / DKFZ neuropathology methylation-classification ecosystem.
结合国内临床样本进行验证与校准，贴合本地科研与样本场景。Validated and calibrated with domestic clinical samples for local research settings.
校准概率 + 三态弃判 + 离群检测，测不准即明确弃判。Calibrated probabilities, three-state abstention and out-of-distribution detection — uncertainty is reported, not hidden.
侯仰昊博士在德国海德堡大学神经病理科完成医学博士训练，师从甲基化分类体系奠基人之一、WHO 肿瘤分类指南编委 Andreas von Deimling 教授，系统掌握中枢神经系统肿瘤的甲基化分型、组织学与分子诊断，并具备 R 语言甲基化数据分析（Nanopore / Illumina / NGS）能力。Dr. Hou completed his doctoral training at Heidelberg University's Department of Neuropathology under Prof. Andreas von Deimling, mastering CNS-tumor methylation classification, histology and molecular diagnostics, with R-based methylation analysis across Nanopore, Illumina and NGS.
现任重庆医科大学基础医学院病理学系讲师，并担任分子医学检测中心临床病理医师与甲基化平台负责人，持续从事中枢神经系统肿瘤甲基化谱分类与 AI 算法研究，将国际前沿方法学与本地临床样本相结合——这正是默赛生分类服务的根基。He is now a lecturer in Pathology at Chongqing Medical University and serves as clinical pathologist and methylation-platform lead at the Molecular Medicine Testing Center, continuing research on CNS-tumor methylation classification and AI algorithms that bridges international methodology with local clinical samples — the foundation of Mosaisheng's services.
国家神经疾病医学中心胶质瘤 MDT 专科联盟理事 · 欧洲神经肿瘤组委会成员 · 欧洲神经病理学组会委员 · 中国微循环学会转化医学专业青年委员会委员Council member, National Glioma MDT Alliance · member, European neuro-oncology committee · member, European neuropathology working group · youth committee, Chinese Society for Microcirculation (Translational Medicine)
创始人长期从事神经病理临床与分子诊断工作。这份一线经验让我们更理解临床端的真实需求，能为课题提供更贴近临床验证场景的科研方向与内容指导——这也是默赛生科研服务的底层支撑。The founder's ongoing work in clinical neuropathology and molecular diagnostics keeps our research services close to real clinical needs, enabling study guidance grounded in real-world validation — the foundation beneath Mosaisheng's research services.
说明：本栏目仅展示创始人的临床与科研背景，用以支撑科研服务能力，不构成对外诊疗或会诊服务。Note: this section presents the founder's clinical and research background to support our research services; it is not an offer of clinical diagnosis or consultation.
无论是甲基化检测、聚类与数据分析，还是课题设计与文章指导，欢迎与我们联系。Whether for methylation profiling, clustering & data analysis, or study design & manuscript guidance — we would be glad to hear from you.
